Akero Therapeutics Inc (NASDAQ: AKRO)’s stock price has gone rise by 1.73 in comparison to its previous close of 50.73, however, the company has experienced a 12.20% increase in its stock price over the last five trading days. accessnewswire.com reported 2025-06-03 that NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc. (“Akero”or “the Company”) (NASDAQ:AKRO). Investors who purchased Akero securities prior to September 13, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/AKRO.
Is It Worth Investing in Akero Therapeutics Inc (NASDAQ: AKRO) Right Now?
Company’s 36-month beta value is -0.16.Analysts have differing opinions on the stock, with 9 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for AKRO is 71.70M, and currently, short sellers hold a 8.78% ratio of that floaft. The average trading volume of AKRO on June 04, 2025 was 1.41M shares.
AKRO’s Market Performance
AKRO stock saw an increase of 12.20% in the past week, with a monthly gain of 15.02% and a quarterly increase of 15.90%. The volatility ratio for the week is 1.83%, and the volatility levels for the last 30 days are 6.31% for Akero Therapeutics Inc (AKRO). The simple moving average for the last 20 days is 16.50% for AKRO’s stock, with a simple moving average of 43.84% for the last 200 days.
Analysts’ Opinion of AKRO
Many brokerage firms have already submitted their reports for AKRO stocks, with BofA Securities repeating the rating for AKRO by listing it as a “Buy.” The predicted price for AKRO in the upcoming period, according to BofA Securities is $63 based on the research report published on January 30, 2025 of the current year 2025.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see AKRO reach a price target of $72, previously predicting the price at $50. The rating they have provided for AKRO stocks is “Buy” according to the report published on January 27th, 2025.
Citigroup gave a rating of “Buy” to AKRO, setting the target price at $65 in the report published on November 18th of the previous year.
AKRO Trading at 23.11% from the 50-Day Moving Average
After a stumble in the market that brought AKRO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -11.63% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AKRO starting from Lamy Patrick, who sale 4,000 shares at the price of $50.00 back on May 22 ’25. After this action, Lamy Patrick now owns 33,492 shares of Akero Therapeutics Inc, valued at $200,000 using the latest closing price.
PATRICK D LAMY, the Officer of Akero Therapeutics Inc, proposed sale 10,000 shares at $48.35 during a trade that took place back on May 22 ’25, which means that PATRICK D LAMY is holding shares at $483,500 based on the most recent closing price.
Stock Fundamentals for AKRO
The total capital return value is set at -0.28. Equity return is now at value -27.92, with -26.06 for asset returns.
Based on Akero Therapeutics Inc (AKRO), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -36.91. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -121.42.
Currently, EBITDA for the company is -285.42 million with net debt to EBITDA at 0.65. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.80.
Conclusion
In a nutshell, Akero Therapeutics Inc (AKRO) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
